



## Charles River Laboratories Announces Organizational Changes to Enhance Global Capabilities

December 9, 2013

WILMINGTON, Mass.--(BUSINESS WIRE)--Dec. 9, 2013-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced organizational changes which are designed to continue to improve the Company's operating efficiency across its global portfolio and enhance its ability to meet the needs of its clients. These changes represent the next step in Charles River's continuing effort to position the Company as the partner of choice for early-stage drug development and to drive future growth.

James C. Foster, Chairman, President and Chief Executive Officer, said, "In a market environment which is rapidly changing, we have continued to refine and enhance our competitive position through a combination of portfolio expansion, organizational changes, efficiency initiatives, improved data infrastructure and increasing scientific expertise. The changes we are announcing today are the logical evolution of these ongoing efforts, which we believe will ensure our clients a consistent and superior experience across our global organization. Furthermore, our intensified emphasis on efficiency will enable us to meet our clients' expectations while maintaining and enhancing our reputation for service, responsiveness and scientific excellence."

### Enhanced Efficiency Initiatives

The organizational changes are designed to further enhance the Company's worldwide productivity initiatives and promote the global management of its Research Models and Services (RMS) and Preclinical Services (PCS) businesses. The respective organizational changes are as follows:

Jörg Geller, D.V.M., Ph.D., previously Corporate Executive Vice President and President, European & Asian Operations, will now directly oversee a global initiative to enhance efficiency and drive increased productivity across all of Charles River's businesses worldwide. In his new role, Dr. Geller will assume the title of Corporate Executive Vice President, Global Productivity and Efficiency. Dr. Geller will be responsible for intensifying the Company's focus on driving productivity, while retaining its reputation for service, responsiveness and scientific excellence. This has become increasingly important to continue to meet clients' expectations and maintain Charles River's strong competitive position. Dr. Geller will lead a cross-sectional team of Charles River's functional and business-unit leaders that will be tasked with the critical initiative to drive increased productivity and efficiency at an accelerated pace.

### RMS and PCS Management Structure

In conjunction with Dr. Geller assuming this new role, Davide Molho, D.V.M., previously Corporate Executive Vice President and President, North American Operations, will assume a broader range of responsibilities with global oversight of the RMS and PCS businesses. In his new role, Dr. Molho will assume the title of Corporate Executive Vice President and President, Global Research Models & Services and Preclinical Services Operations. Dr. Molho will be responsible for transitioning from a unified, regional business alignment, which was implemented in 2011, to a more fully integrated, global organizational structure across North America, Europe and Asia.

Colin Dunn, Ph.D., has been promoted to the position of Corporate Senior Vice President and General Manager, Research Models & Services, Europe and Asia. Dr. Dunn was previously responsible for European RMS operations, and in his expanded role, will oversee all of the Company's RMS operations in Europe, Japan and China. Dr. Dunn will report to Dr. Molho, as will Dr. Brian Bathgate, Corporate Senior Vice President, European Preclinical Services. Dr. Bathgate will continue to oversee European preclinical operations, as well as global PCS Laboratory Services.

Dr. Emily Hickey, who joined Charles River in October 2013 as Corporate Vice President, In Vivo Discovery Research Services, will now report directly to Mr. Foster. This reporting relationship reflects the strategic importance of the Discovery Research Services business, as Dr. Hickey helps drive the growth and expansion of this emerging outsourced service opportunity. This reporting change parallels the organizational structure that was previously established for the Company's Endotoxin and Microbial Detection business. Foster Jordan, Corporate Senior Vice President, Endotoxin & Microbial Detection, will continue to report directly to Mr. Foster.

Mr. Foster continued, "I am confident that the extensive experience and strategic leadership capabilities of these senior executives will contribute to the continued growth of Charles River."

### Caution Concerning Forward-Looking Statements

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements include statements in this press release regarding future demand for drug discovery and development products and services including the outsourcing of these services; the specific contributions of members of Charles River's management team and the organizational changes; and expectations regarding market and industry conditions. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements, including the timing and magnitude of our share repurchases. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2013, as well as other filings we make with the Securities and Exchange Commission. Charles River assumes no obligation and expressly disclaims any duty to update information contained in this release except as required by law.

### About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development

and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit [www.criver.com](http://www.criver.com).

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

Investor Contact:

Susan E. Hardy, 781-222-6190

Corporate Vice President, Investor Relations

[susan.hardy@crl.com](mailto:susan.hardy@crl.com)

or

Media Contact:

Amy Cianciaruso, 781-222-6168

Executive Director, Public Relations

[amy.cianciaruso@crl.com](mailto:amy.cianciaruso@crl.com)